301075 多瑞医药
午间休市 12-11 11:30:00
资讯
新帖
简况
多瑞医药(301075)披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告,11月24日股价上涨3.09%
证券之星 · 11-24
多瑞医药(301075)披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告,11月24日股价上涨3.09%
股市必读:多瑞医药(301075)11月13日董秘有最新回复
证券之星 · 11-14
股市必读:多瑞医药(301075)11月13日董秘有最新回复
多瑞医药:公司自有产品尚未布局流感方面的药物
证券之星 · 11-13
多瑞医药:公司自有产品尚未布局流感方面的药物
多瑞医药(301075)披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告,11月11日股价上涨0.02%
证券之星 · 11-11
多瑞医药(301075)披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告,11月11日股价上涨0.02%
多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司
智通财经 · 11-07
多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司
多瑞医药(301075)2025年三季报简析:净利润同比下降27.23%
证券之星 · 10-25
多瑞医药(301075)2025年三季报简析:净利润同比下降27.23%
多瑞医药:持续提升信息披露水平
证券之星 · 10-24
多瑞医药:持续提升信息披露水平
股市必读:多瑞医药(301075)股东户数0.64万户,较上期减少16.6%
中金财经 · 10-24
股市必读:多瑞医药(301075)股东户数0.64万户,较上期减少16.6%
多瑞医药(301075.SZ)发布前三季度业绩,归母净亏损7972.77万元
智通财经 · 10-23
多瑞医药(301075.SZ)发布前三季度业绩,归母净亏损7972.77万元
多瑞医药(301075)披露部分募投项目终止并用剩余募集资金偿还银行贷款及补流公告,10月23日股价下跌4.95%
证券之星 · 10-23
多瑞医药(301075)披露部分募投项目终止并用剩余募集资金偿还银行贷款及补流公告,10月23日股价下跌4.95%
净利持续亏损 多瑞医药易主
市场资讯 · 10-14
净利持续亏损 多瑞医药易主
多瑞医药(301075)披露筹划控制权变更进展暨复牌公告,10月14日股价上涨4.94%
证券之星 · 10-14
多瑞医药(301075)披露筹划控制权变更进展暨复牌公告,10月14日股价上涨4.94%
多瑞医药最新公告:控股股东、实控人变更为王庆太、崔子浩、曹晓兵 股票明起复牌
证券之星 · 10-13
多瑞医药最新公告:控股股东、实控人变更为王庆太、崔子浩、曹晓兵 股票明起复牌
多瑞医药最新公告:筹划控制权变更 股票自10月9日起继续停牌
证券之星 · 09-30
多瑞医药最新公告:筹划控制权变更 股票自10月9日起继续停牌
多家A股公司控制权拟变更!301075,002370,300692,停牌!300948,复牌!
e公司 · 09-28
多家A股公司控制权拟变更!301075,002370,300692,停牌!300948,复牌!
多瑞医药(301075.SZ):公司控制权或将发生变更 9月29日起停牌
智通财经 · 09-28
多瑞医药(301075.SZ):公司控制权或将发生变更 9月29日起停牌
多瑞医药宣布因潜在股权变更,公司股票将从9月29日起暂停交易
美股速递 · 09-28
多瑞医药宣布因潜在股权变更,公司股票将从9月29日起暂停交易
异动快报:多瑞医药(301075)8月29日11点18分触及涨停板
证券之星 · 08-29
异动快报:多瑞医药(301075)8月29日11点18分触及涨停板
A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。
金融界 · 08-29
A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。
多瑞医药(301075)2025年中报简析:净利润同比下降1197.26%
证券之星 · 08-28
多瑞医药(301075)2025年中报简析:净利润同比下降1197.26%
加载更多
公司概况
公司名称:
西藏多瑞医药股份有限公司
所属行业:
医药制造业
上市日期:
2021-09-29
主营业务:
西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。
发行价格:
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":51.72,"timestamp":1765427040000,"preClose":51.9,"halted":0,"volume":366300,"delay":0,"changeRate":-0.0035,"floatShares":80000000,"shares":80000000,"eps":-1.5665,"marketStatus":"午间休市","change":-0.18,"latestTime":"12-11 11:30:00","open":51.6,"high":52.55,"low":51.05,"amount":18950500,"amplitude":0.0289,"askPrice":51.74,"askSize":1,"bidPrice":51.71,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-1.5665,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765429200000},"marketStatusCode":3,"adr":0,"adjPreClose":51.9,"symbolType":"stock","openAndCloseTimeList":[[1765416600000,1765423800000],[1765429200000,1765436400000]],"highLimit":57.09,"lowLimit":46.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"isCdr":false,"pbRate":6.96,"roa":"--","roe":"--","epsLYR":-0.79,"committee":0.369863,"marketValue":4138000000,"turnoverRate":0.0046,"status":1,"floatMarketCap":4138000000},"requestUrl":"/m/hq/s/301075","defaultTab":"news","newsList":[{"id":"2585498870","title":"多瑞医药(301075)披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告,11月24日股价上涨3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498870?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:21","pubTimestamp":1763994070,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,多瑞医药报收于49.1元,较前一交易日上涨3.09%,最新总市值为39.28亿元。公司近日发布公告称,西藏多瑞医药控股股东西藏嘉康及其一致行动人舟山清畅与王庆太、崔子浩、曹晓兵签署股份转让协议,拟转让公司29.60%股份。同时,王庆太、曹晓兵拟通过要约收购方式增持24.30%股份,西藏嘉康将预受要约并放弃对应股份表决权。公司已收到深交所出具的股份协议转让确认书,尚需办理过户登记,存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2583313511","title":"股市必读:多瑞医药(301075)11月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2583313511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583313511?lang=zh_cn&edition=full","pubTime":"2025-11-14 04:54","pubTimestamp":1763067251,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘,多瑞医药报收于55.76元,下跌3.51%,换手率3.39%,成交量2.71万手,成交额1.51亿元。董秘最新回复投资者: 您好,贵公司有没有可以用于流感方面的?感谢您对公司的关注!交易信息汇总资金流向11月13日主力资金净流出105.88万元;游资资金净流入323.46万元;散户资金净流出217.57万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400003670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2583559069","title":"多瑞医药:公司自有产品尚未布局流感方面的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559069?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019946,"startTime":"0","endTime":"0","summary":"证券之星消息,多瑞医药(301075)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,贵公司有没有可以用于流感方面的?多瑞医药回复:尊敬的投资者您好,公司自有产品尚未布局流感方面的药物。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2582036089","title":"多瑞医药(301075)披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告,11月11日股价上涨0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582036089","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582036089?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:44","pubTimestamp":1762872263,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘,多瑞医药报收于56.53元,较前一交易日上涨0.02%,最新总市值为45.22亿元。同日,多瑞医药发布公告称,公司控股股东西藏嘉康及其一致行动人舟山清畅与王庆太、崔子浩、曹晓兵于近日签署《股份转让协议之补充协议》,对原协议的转让价款支付安排、业绩承诺及补偿等内容进行了调整。本次权益变动后,王庆太、崔子浩、曹晓兵将成为公司新实际控制人。该事项尚需深交所合规性确认及中登公司办理过户登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2581074100","title":"多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581074100","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581074100?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:06","pubTimestamp":1762502764,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)发布公告,根据公司经营及战略发展的需要,为优化公司总部管理职能,公司成立全资子公司西藏瑞升祥医药有限公司,注册资本200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1161","09939","BK1574","BK1515","159938","301075"],"gpt_icon":0},{"id":"2578257305","title":"多瑞医药(301075)2025年三季报简析:净利润同比下降27.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578257305","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578257305?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:11","pubTimestamp":1761343878,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期多瑞医药发布2025年三季报。根据财报显示,多瑞医药净利润同比下降27.23%。截至本报告期末,公司营业总收入1.37亿元,同比下降43.07%,归母净利润-7972.77万元,同比下降27.23%。按单季度数据看,第三季度营业总收入3042.54万元,同比下降66.29%,第三季度归母净利润-3722.41万元,同比上升37.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"gpt_icon":0},{"id":"2577556066","title":"多瑞医药:持续提升信息披露水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2577556066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577556066?lang=zh_cn&edition=full","pubTime":"2025-10-24 08:45","pubTimestamp":1761266712,"startTime":"0","endTime":"0","summary":"证券之星消息,多瑞医药(301075)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问:根据公告原控股股东对公司2025-2027年业绩作出承诺,若未达标将现金补偿。请问公司是否会同步建立市值管理机制,如设立市值考核指标、引入专业机构、加强投资者关系管理,以保障股东利益与市场预期稳定?多瑞医药回复:尊敬的投资者,您好!公司高度重视市值管理相关工作,后续将持续提升信息披露水平,优化市值管理机制,提高投资者沟通交流质量,及时向资本市场传递公司价值。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2577555475","title":"股市必读:多瑞医药(301075)股东户数0.64万户,较上期减少16.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577555475","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577555475?lang=zh_cn&edition=full","pubTime":"2025-10-24 08:10","pubTimestamp":1761264658,"startTime":"0","endTime":"0","summary":"来自:截至2025年9月30日,公司股东户数较6月30日减少16.6%,户均持股数量上升至1.26万股。股东户数变动截至2025年9月30日,公司股东户数为6361.0户,较6月30日减少1266.0户,减幅为16.6%。第二届监事会第二十三次会议决议公告西藏多瑞医药股份有限公司第二届监事会第二十三次会议于2025年10月22日召开,应出席监事3人,实际出席3人,会议合法有效。该事项已获董事会、监事会审议通过,尚需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251024/31732878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2577037127","title":"多瑞医药(301075.SZ)发布前三季度业绩,归母净亏损7972.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577037127","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577037127?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:17","pubTimestamp":1761211074,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)发布2025年三季度报告,该公司前三季度营业收入为1.37亿元,同比减少43.07%。归属于上市公司股东的净亏损为7972.77万元。归属于上市公司股东的扣除非经常性损益的净亏损为8494.85万元。基本每股亏损为1.0064元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"多瑞医药(301075.SZ)发布前三季度业绩,归母净亏损7972.77万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2577374385","title":"多瑞医药(301075)披露部分募投项目终止并用剩余募集资金偿还银行贷款及补流公告,10月23日股价下跌4.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577374385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577374385?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:17","pubTimestamp":1761211022,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘,多瑞医药报收于55.72元,较前一交易日下跌4.95%,最新总市值为44.58亿元。该股当日开盘58.0元,最高59.49元,最低52.25元,成交额达3.81亿元,换手率为8.59%。公司近日发布公告称,拟召开2025年第二次临时股东大会,审议《关于部分募投项目终止、结项并将剩余募集资金偿还银行贷款和永久补充流动资金的议案》等共计11项议案。此次会议定于2025年11月10日举行,股权登记日为2025年11月5日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300026572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2575255502","title":"净利持续亏损 多瑞医药易主","url":"https://stock-news.laohu8.com/highlight/detail?id=2575255502","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575255502?lang=zh_cn&edition=full","pubTime":"2025-10-14 23:59","pubTimestamp":1760457540,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 10月13日深夜,多瑞医药复牌方案出炉,公司实控人拟变更为王庆太、崔子浩、曹晓兵。值得一提的是,此次交易接盘方3名自然人均无医药背景。而多瑞医药目前业绩承压,今年上半年净利出现亏损。 资料显示,多瑞医药主要从事化学药品制剂及中间体、原料药的研发、生产和销售。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-14/doc-inftwtaz1730810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2575298456","title":"多瑞医药(301075)披露筹划控制权变更进展暨复牌公告,10月14日股价上涨4.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575298456","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575298456?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:25","pubTimestamp":1760433929,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘,多瑞医药报收于42.06元,较前一交易日上涨4.94%,最新总市值为33.65亿元。本次权益变动后,王庆太、崔子浩、曹晓兵将合计持有公司29.60%股份及表决权,成为公司控股股东、实际控制人。公司股票自2025年10月14日上午开市起复牌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400054176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2575283638","title":"多瑞医药最新公告:控股股东、实控人变更为王庆太、崔子浩、曹晓兵 股票明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2575283638","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575283638?lang=zh_cn&edition=full","pubTime":"2025-10-13 23:39","pubTimestamp":1760369978,"startTime":"0","endTime":"0","summary":"多瑞医药公告称,公司控股股东西藏嘉康及其一致行动人舟山清畅与受让方王庆太、崔子浩、曹晓兵签署《股份转让协议》,拟合计转让公司无限售流通股2368万股,占公司总股本的29.60%。权益变动后,王庆太、崔子浩、曹晓兵合计将拥有公司29.60%的股份及该等股份对应的表决权,公司控股股东、实际控制人变更为王庆太、崔子浩、曹晓兵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300025844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2571348829","title":"多瑞医药最新公告:筹划控制权变更 股票自10月9日起继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2571348829","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571348829?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:21","pubTimestamp":1759224107,"startTime":"0","endTime":"0","summary":"多瑞医药(301075.SZ)公告称,公司于2025年9月26日收到公司控股股东西藏嘉康时代科技发展有限公司、实际控制人邓勇的通知,其正在筹划公司控制权变更相关事宜,该事项可能导致公司控股股东、实际控制人发生变更。截至目前,相关各方正在积极推进本次交易的各项工作,整体方案仍在协商,交易各方尚未签署正式协议,公司预计无法在2025年10月9日上午开市起复牌。经公司向深圳证券交易所申请,公司股票自2025年10月9日上午开市起继续停牌,预计停牌时间不超过3个交易日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000028423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2570524849","title":"多家A股公司控制权拟变更!301075,002370,300692,停牌!300948,复牌!","url":"https://stock-news.laohu8.com/highlight/detail?id=2570524849","media":"e公司","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570524849?lang=zh_cn&edition=full","pubTime":"2025-09-28 18:03","pubTimestamp":1759053780,"startTime":"0","endTime":"0","summary":" 9月28日晚间,多瑞医药、亚太药业和中环环保等多家A股公司披露筹划控制权变更事项。冠中生态则披露控股股东拟变更为深蓝财鲸。 具体来看,多瑞医药公告,公司控股股东西藏嘉康时代科技发展有限公司、实际控制人邓勇正在筹划公司控制权变更相关事宜,可能导致公司控股股东、实际控制人发生变更。经申请,公司股票自2025年9月29日起停牌,预计停牌时间不超过2个交易日。公司股票及可转债9月29日复牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-09-28/doc-infrzyrp2719117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0218","301075","300692","002370","159982","399300","BK0135","BK0132","BK0239","300948","BK0150"],"gpt_icon":0},{"id":"2570845386","title":"多瑞医药(301075.SZ):公司控制权或将发生变更 9月29日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2570845386","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570845386?lang=zh_cn&edition=full","pubTime":"2025-09-28 16:57","pubTimestamp":1759049864,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)公告,公司控股股东西藏嘉康时代科技发展有限公司(简称“西藏嘉康”)、实际控制人邓勇先生正在筹划公司控制权变更相关事宜,该事项可能导致公司控股股东、实际控制人发生变更。公司股票自2025年9月29日(星期一)上午开市起停牌,预计停牌时间不超过2个交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"多瑞医药(301075.SZ):公司控制权或将发生变更 9月29日起停牌","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"1108243935","title":"多瑞医药宣布因潜在股权变更,公司股票将从9月29日起暂停交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1108243935","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108243935?lang=zh_cn&edition=full","pubTime":"2025-09-28 16:57","pubTimestamp":1759049833,"startTime":"0","endTime":"0","summary":"多瑞医药宣布,因潜在的股权变更事宜,公司股票将从9月29日起暂停交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2563525092","title":"异动快报:多瑞医药(301075)8月29日11点18分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2563525092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563525092?lang=zh_cn&edition=full","pubTime":"2025-08-29 11:20","pubTimestamp":1756437631,"startTime":"0","endTime":"0","summary":"证券之星8月29日盘中消息,11点18分多瑞医药触及涨停板。目前价格53.28,上涨20.0%。其所属行业化学制药目前上涨。该股为化学原料药,医药,西藏概念概念热股,当日化学原料药概念上涨1.31%,医药概念上涨0.99%,西藏概念概念上涨0.72%。8月28日的资金流向数据方面,主力资金净流入250.96万元,占总成交额0.97%,游资资金净流出1168.54万元,占总成交额4.51%,散户资金净流入917.58万元,占总成交额3.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900016916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2563209143","title":"A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2563209143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563209143?lang=zh_cn&edition=full","pubTime":"2025-08-29 10:26","pubTimestamp":1756434388,"startTime":"0","endTime":"0","summary":"A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/29102652792123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301075","BK1191","BK0185","300111","BK0239","159982","BK0156","BK0250","399300","BK0012","BK0054","BK0028","688799","003020","600521","BK0188","300636","BK0201","01477","BK0070","BK1574"],"gpt_icon":0},{"id":"2562459776","title":"多瑞医药(301075)2025年中报简析:净利润同比下降1197.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562459776","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562459776?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:35","pubTimestamp":1756334141,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期多瑞医药发布2025年中报。根据财报显示,多瑞医药净利润同比下降1197.26%。截至本报告期末,公司营业总收入1.07亿元,同比下降29.13%,归母净利润-4250.36万元,同比下降1197.26%。按单季度数据看,第二季度营业总收入5712.92万元,同比下降20.57%,第二季度归母净利润-2690.54万元,同比下降3540.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800007344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765427089718,"stockEarnings":[{"period":"1week","weight":0.0532},{"period":"1month","weight":-0.0817},{"period":"3month","weight":0.1833},{"period":"6month","weight":0.8907},{"period":"1year","weight":1.4493},{"period":"ytd","weight":1.8881}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0065},{"period":"6month","weight":0.155},{"period":"1year","weight":0.1396},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6361人(较上一季度减少16.60%)","perCapita":"12576股","listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","registeredCapital":"8000万元","survey":" 西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。","listedPrice":27.27},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}